New Jersey Senate Bill SCR146

New Jersey 2022-2023 Regular Session

• Introduced: 6/26/23
• Refer: 6/26/23

Caption

Urges Governor to direct all relevant State departments and agencies to help decrease number of fatalities caused by atherosclerotic cardiovascular disease.

Impact

The resolution calls for a multi-faceted strategy where the Governor would encourage departments to update existing health policies and collaborate with federal agencies to expand cardiovascular health initiatives. It notes that New Jersey spends about $3.39 billion annually on direct and indirect costs associated with ASCVD care, thus reinforcing the importance of investing in effective healthcare policies. Implementing this resolution could lead to better health outcomes for residents suffering from cardiovascular conditions and may reduce the economic burden on the state's healthcare system.

Summary

SCR146 is a Senate Concurrent Resolution introduced to urge the Governor of New Jersey to direct all relevant state departments and agencies to take measures aimed at decreasing fatalities caused by atherosclerotic cardiovascular disease (ASCVD). Recognizing that cardiovascular disease remains the leading cause of death in the U.S., the resolution highlights the alarming statistics indicating that approximately 21 million Americans are diagnosed with ASCVD, which is linked to elevated levels of low-density lipoprotein cholesterol (LDL-C). The resolution emphasizes the necessity for a comprehensive approach to managing cardiovascular health, which includes improving screening and treatment processes.

Contention

While the resolution has strong supportive data advocating for public health improvements, potential points of contention could arise surrounding the allocation of state resources and the prioritization of cardiovascular health compared to other pressing health issues. Concerns about the effectiveness of governmental health initiatives and the actual implementation of the proposed measures may influence support from various stakeholders. Stakeholders might debate the extent of state versus federal responsibilities in tackling public health issues like ASCVD.